Logo

CEROW

CERo Therapeutics Holdings, Inc.

CEROW

CERo Therapeutics Holdings, Inc. • NASDAQ
$0.01 ▼ -32.97% (-0.00)
Market Cap $3.64 M
52w High $0.01
52w Low $0.01
Dividend Yield 0%
P/E 0
Volume 3.00K
Outstanding Shares 595.96M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.363M ▼ $-11.506M ▼ 0% $-9.1 ▲ $-4.363M ▲
Q2-2025 $0 $4.724M ▼ $-5.417M ▼ 0% $-61.71 ▼ $-5.163M ▼
Q1-2025 $0 ▼ $4.951M ▲ $-5.106M ▼ 0% ▼ $-3.18 ▼ $-4.837M ▼
Q4-2024 $1.163M ▲ $2.384M ▼ $1.244M ▲ 107.008% ▲ $0.56 ▲ $1.546M ▲
Q3-2024 $0 $4.402M $-4.228M 0% $-17.02 $-4.402M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.022M ▼ $3.911M ▼ $8.455M ▲ $-4.543M ▼
Q2-2025 $3.803M ▼ $6.202M ▼ $7.836M ▼ $-1.634M ▼
Q1-2025 $5.204M ▲ $7.991M ▲ $8.321M ▲ $-329.386K ▲
Q4-2024 $3.327M ▼ $6.207M ▼ $8.101M ▼ $-1.895M ▲
Q3-2024 $3.38M $6.492M $10.194M $-3.702M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.856M ▲ $-3.205M ▲ $500K ▲ $1.425M ▼ $-1.281M ▲ $-3.205M ▲
Q2-2025 $-5.417M ▼ $-4.623M ▼ $0 $2.722M ▼ $-1.901M ▼ $-4.623M ▼
Q1-2025 $-5.106M ▼ $-4.446M ▼ $0 ▲ $6.322M ▲ $1.876M ▲ $-4.446M ▼
Q4-2024 $-1.048M ▼ $-1.54M ▲ $-4 ▼ $1.487M ▼ $-53.144K ▲ $4.146M ▲
Q3-2024 $-4.227K $-2.758M $0 $2.492M $-266.822K $-1.318M

Five-Year Company Overview

Income Statement

Income Statement CERo is still a pure research-stage biotech with no product sales yet. Its income statement is driven almost entirely by research and corporate overhead, leading to ongoing losses, which is typical at this stage. The swings in per-share figures reflect changes in share count and capital structure more than big shifts in the underlying business. Until there is clear clinical progress or partnerships, the financial story is about controlled spending to advance trials rather than revenue growth or profitability.

Balance Sheet

Balance Sheet The company operates with a very lean balance sheet: modest assets, historically centered on cash, and no reported financial debt. Equity has been thin and has even dipped negative at times, which underscores how dependent the business is on outside funding. The lack of debt reduces financial strain, but the small asset base highlights that CERo is still a very small, early-stage enterprise with limited buffer if funding conditions tighten.

Cash Flow

Cash Flow Cash is flowing out of the business to pay for research, clinical development, and operations, with no offsetting inflows from sales yet. Investment in physical assets appears minimal, so most cash burn is tied directly to people, lab work, and trials. This makes CERo highly sensitive to capital markets: progress depends on its ability to continue raising funds or securing non-dilutive support such as grants or partnerships. Investors should watch updates on cash runway and any new financings closely.

Competitive Edge

Competitive Edge CERo sits in a highly competitive corner of biotech—cell therapies for cancer—where many larger and better-funded companies are active. Its edge is a differentiated mechanism that attempts to combine killing cancer cells with engulfing and presenting them to the immune system, which could stand out among more conventional cell therapies. Its patent estate and “first-in-class” positioning around this specific receptor design provide some protection, but real competitive strength will ultimately depend on whether clinical data show clear benefits versus existing and emerging treatments.

Innovation and R&D

Innovation and R&D Innovation is the heart of CERo’s story. The company is developing a novel CER-T platform that aims to tap both innate and adaptive immunity by targeting an “eat me” signal on cancer cells. The lead program is in early clinical testing for a hard-to-treat blood cancer, supported by orphan drug status, with plans to expand into solid tumors if early data are favorable. The platform appears flexible, allowing next-generation constructs and combinations with other therapies, and is backed by a long-dated patent portfolio. However, all of this remains hypothesis-driven until more human trial results are available.

Summary

CERo Therapeutics is a very early-stage oncology biotech whose value today rests almost entirely on the scientific promise of its CER-T cell platform rather than on current financial performance. The company has no revenue, a small and changing capital base, and steady cash burn that will require ongoing external financing. On the positive side, it has a clearly differentiated approach, a focused lead program, intellectual property protection, and a roadmap for expanding into solid tumors and more advanced constructs. The main uncertainties are classic for this type of company: whether the science translates into meaningful clinical benefit and safety, how fast and costly development will be, and whether CERo can consistently secure the funding and partnerships needed to move through trials. It is a high-risk, research-driven story where future clinical readouts and financing developments are the key things to monitor.